Truist Financial Cuts Abivax (NASDAQ:ABVX) Price Target to $151.00

Abivax (NASDAQ:ABVX) had its price target dropped by Truist Financial from $155.00 to $151.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 49.31% from the stock’s previous close.

A number of other research analysts have also weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Guggenheim reissued a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Barclays reaffirmed an “overweight” rating and issued a $148.00 price target on shares of Abivax in a research report on Tuesday. Wolfe Research set a $136.00 price target on Abivax in a research note on Wednesday, June 3rd. Finally, Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and increased their price objective for the stock from $108.00 to $158.00 in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Abivax currently has an average rating of “Moderate Buy” and an average price target of $156.69.

Abivax Stock Down 2.2%

NASDAQ ABVX opened at $101.14 on Tuesday. Abivax has a 52 week low of $69.81 and a 52 week high of $148.83. The business has a 50 day moving average price of $120.76 and a 200-day moving average price of $117.67. The company has a market cap of $8.83 billion, a price-to-earnings ratio of -19.50 and a beta of 0.96.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million. On average, equities research analysts anticipate that Abivax will post -3.22 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

Several institutional investors have recently modified their holdings of ABVX. Westfield Capital Management Co. LP purchased a new stake in shares of Abivax during the 4th quarter worth approximately $136,199,000. Lord Abbett & CO. LLC grew its holdings in Abivax by 152.4% during the fourth quarter. Lord Abbett & CO. LLC now owns 849,732 shares of the company’s stock valued at $114,591,000 after purchasing an additional 513,026 shares during the period. Eversept Partners LP grew its holdings in Abivax by 42.0% during the first quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock valued at $104,048,000 after purchasing an additional 276,589 shares during the period. Janus Henderson Group PLC increased its position in Abivax by 31.6% in the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after buying an additional 211,068 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Abivax by 40.9% in the first quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock valued at $81,923,000 after buying an additional 213,440 shares during the period. 47.91% of the stock is owned by institutional investors.

Key Headlines Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax said it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. The company also reported €402.4 million in cash, cash equivalents and short-term investments at June 30, plus €767.1 million in net proceeds from its early-July offering, extending its cash runway into the fourth quarter of 2029. Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
• Positive Sentiment: The completed buyback of royalty certificates materially reduces a potential royalty overhang and leaves Abivax debt-free, improving financial flexibility ahead of possible commercialization. The company also appointed Tim Kelly as chief technical officer to support manufacturing, quality and commercial-supply readiness. Abivax Presents Business Updates and First Half 2026 Financial Results
• Neutral Sentiment: Analysts maintain an average “Moderate Buy” rating, suggesting that Wall Street remains constructive on the company’s longer-term prospects, although the stock’s roughly $9 billion valuation depends heavily on the success and regulatory progress of obefazimod. Abivax Receives Average Rating of Moderate Buy
• Neutral Sentiment: Chris Rabbat will succeed Fabio Cataldi as chief medical officer. The leadership transition may support continued clinical and regulatory execution, but it also introduces an additional management change as Abivax approaches key development milestones. Abivax Announces Chief Medical Officer Succession
• Negative Sentiment: Abivax reported a quarterly loss of $1.71 per share, substantially worse than the $0.92 consensus estimate. Although quarterly revenue of $1.37 million exceeded the $0.80 million forecast, the wider-than-expected loss and continued clinical-stage cash burn are weighing on sentiment. Abivax Releases Earnings Results and Misses EPS Expectations

About Abivax

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.